Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations (SOD-1)

This study has been completed.
Sponsor:
Collaborators:
Muscular Dystrophy Association
ALS Association
Information provided by (Responsible Party):
Ionis Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01041222
First received: December 30, 2009
Last updated: April 12, 2012
Last verified: April 2012